| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||||
Revenues | ||||||||||
102,428 | 84,452 | 36,567 | 19,389 | 39,539 | 45,870 | 24,133 | 21,655 | 10,319 | 20,805 | 22,187 |
Operating expenses: | ||||||||||
Research and development | ||||||||||
145,922 | 114,866 | 65,728 | 65,618 | 67,198 | 56,974 | 37,039 | 31,709 | 32,098 | 33,154 | 28,984 |
General and administrative | ||||||||||
61,686 | 46,736 | 27,200 | 26,330 | 19,197 | 15,677 | 13,800 | 12,144 | 14,042 | 12,586 | 12,605 |
Total operating expenses | ||||||||||
207,608 | 161,602 | 92,928 | 91,948 | 86,395 | 72,651 | 50,839 | 43,853 | 46,140 | 45,740 | 41,589 |
Loss from operations | ||||||||||
-105,180 | -77,150 | -56,361 | -72,559 | -46,856 | -26,781 | -26,706 | -22,198 | -35,821 | -24,935 | -19,402 |
Interest and other income, net | ||||||||||
9,761 | 8,261 | 1,793 | 887 | 431 | 364 | 82 | - | - | - | 268 |
Loss before income taxes | ||||||||||
-95,419 | -68,889 | -54,568 | -71,672 | -46,425 | -26,417 | -26,624 | - | - | - | - |
Benefit from income taxes | ||||||||||
0 | 0 | 0 | -14 | -5,722 | - | - | - | - | - | - |
Net loss | ||||||||||
-95,419 | -68,889 | -54,568 | -71,658 | - | - | - | - | - | - | - |
Net loss attributable to non-controlling interest | ||||||||||
-233 | -555 | 0 | - | - | - | - | - | - | - | - |
Other income (expense), net | ||||||||||
- | - | - | - | - | - | - | -66 | 71 | 81 | 547 |
Net loss to Sangamo Therapeutics, Inc. stockholders | ||||||||||
-95,186 | -68,334 | -54,568 | -71,658 | -40,703 | -26,417 | -26,624 | -22,264 | -35,750 | -24,854 | -18,587 |
Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share) | ||||||||||
-0.85 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 | -0.44 |
Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) | ||||||||||
112,114 | 96,941 | 78,084 | 70,553 | 69,757 | 67,022 | 55,974 | 52,741 | 50,512 | 45,167 | 42,048 |
Net loss | ||||||||||
-95,186 | -68,334 | -54,568 | -71,658 | -40,703 | - | - | - | - | - | -18,587 |
Collaboration Agreements [Member] | ||||||||||
Revenues | ||||||||||
- | - | - | 18,881 | 37,844 | 43,880 | 21,678 | 18,186 | 6,110 | 16,819 | 21,553 |
Research Grants [Member] | ||||||||||
Revenues | ||||||||||
- | - | - | 508 | 1,695 | 1,990 | 2,455 | 3,469 | 4,209 | 3,986 | 634 |